Introduction
============

The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to rapidly develop new diagnostic, preventive and therapeutic strategies ^[@ref-1]^. Currently, thousands of new COVID-19 patients present for care every day, and many are quickly enrolled in clinical studies. We aimed to investigate the characteristics of the COVID-19 studies registered in ClinicalTrials.gov ^[@ref-2]^, and report the extent to which they have incorporated features that are desirable for generating high-quality evidence.

Methods
=======

We investigated the ClinicalTrials.gov website on April 28, 2020, using the search term: SARS-CoV-2 OR 2019-nCoV OR 2019 novel coronavirus OR severe acute respiratory syndrome coronavirus 2 OR Covid-19. No restrictions were applied. No screening of trials was performed; all results were included regardless of their content.

Stata 15.0 (Stata Corp., College Station, TX, USA) was used for the analysis of study characteristics.

Results
=======

A total of 945 studies on COVID-19 have been registered in ClinicalTrials.gov up to April 29, 2020; 586 studies are interventional (62.0%), and 435 of them (74.2%) are randomized. Among interventional studies, the most frequent allocation scheme is the parallel group assignment (437; 74.6%), followed by single group (111; 18.9%\], sequential (18; 3.1%), factorial (9; 1.5%), and cross-over assignment (11; 1.9%). The majority of the clinical trials are open-label (no masking, 338 \[57.7%\]); however, 57 (9.7%) trials are double-blinded, 41 (7.0%) triple-blinded, 90 (15.4%) quadruple-blinded, and 60 (10.2%) single-blinded. Among observational studies, cohort (222; 64.3%) is the most common study design ( [Table 1](#T1){ref-type="table"}).

###### Characteristics of COVID-19 studies registered in ClinicalTrials.gov (n=945).

  ---------------------------------------------------------------
  Study type                                   N (%)
  -------------------------------------------- ------------------
  Study design (n=945)                         

     Interventional                            586 (62.0)

     Observational                             345 (36.5)

     Expanded access                           14 (1.5)

  Recruitment status (n=945)                   

     Recruiting or enrolling by invitation     453 (47.9)

     Not yet recruiting                        414 (43.8)

     Active, not recruiting                    24 (2.5)

     Completed                                 27 (2.9)

     Withdrawn, terminated or suspended        13 (1.4)

     Available                                 13 (1.4)

  Intervention type (n=945)                    

     Drug                                      405 (42.9)

     Biological (cells, blood sampling, etc)   74 (7.8)

     Diagnostic test                           60 (6.3)

     Device                                    44 (4.7)

     Procedure                                 18 (1.9)

     Behavioral                                20 (2.1)

     Dietary supplement                        9 (1.0)

     Other/Unknown                             315 (33.3)

  Target age (n=945)                           

     Any age                                   165 (17.5)

     Child (\<18 y)                            5 (0.5)

     Child and adult (\<65 y)                  8 (0.8)

     Adult (18--65 y)                          35 (3.7)

     Adult and elderly (≥18 y)                 720 (76.2)

     Elderly (≥66 y)                           12 (1.3)

  Funding (n=945)                              

     NIH or federal                            13 (1.4)

     Industry                                  82 (8.7)

     Industry plus other                       63 (6.7)

     Other (organizations, universities,\      787 (83.2)
     individuals)                              

  Expected trial size (n=931)                  200 (66--504)

     0--100                                    344 (37.0)

     101--1000                                 439 (47.1)

     \>1000                                    148 (15.9)

     Interventional (n=586) \[median\          150 (52--420)
     (IQR)\]                                   

     Observational (n=345) \[median\           300 (100--1,000)
     (IQR)\]                                   

  Study results (n=945)                        

     Not available                             945 (100)

  **Interventional studies (n=586)**           

  Study phase (n=586)                          

     Phase 0, 1, 1/2                           62 (10.6)

     Phase 2, 2/3                              212 (36.2)

     Phase 3, 4                                165 (28.1)

     Not applicable                            147 (25.1)

  Model (n=586)                                

     Parallel assignment                       437 (74.6)

     Single group assignment                   111 (18.9)

     Sequential                                18 (3.1)

     Factorial assignment                      9 (1.5)

     Crossover assignment                      11 (1.9)

  Masking (n=586)                              

     Open label or no masking                  338 (57.7)

     Single-blind                              60 (10.2)

     Double-blind                              57 (9.7)

     Triple-blind                              41 (7.0)

     Quadruple-blind                           90 (15.4)

  Study allocation (n=586)                     

     Randomized                                435 (74.2)

     Non-randomized                            53 (9.1)

     Unknown/missing                           98 (16.7)

  **Observational studies (n=345)**            

  Observational model (n=345)                  

     Cohort                                    222 (64.3)

     Case-control                              34 (9.9)

     Case-only                                 45 (13.0)

     Ecologic or community                     11 (3.2)

     Other                                     33 (9.6)

  Time perspective (n=345)                     

     Prospective                               230 (66.7)

     Retrospective                             58 (16.8)

     Cross-sectional                           31 (9.0)

     Other                                     26 (7.5)
  ---------------------------------------------------------------

Most studies target adult or elderly participants, while 178 (18.8%) enroll children, with only five (0.5%) recruiting exclusively children. Median expected study size is 200 (interquartile range, 66--504), although sample sizes vary from ≤100 (344; 37.0%) to \>1,000 individuals (148; 15.9%). Overall, only 27 of 945 studies (2.9%) have completed recruitment, 453 (47.9%) are actively recruiting subjects, while a large number of studies (414; 43.8%) are not yet actively recruiting participants. Most of the studies are conducted in Europe (n=327), North America (n=217, of which 186 in the US), East Asia (n=102), Africa (n=27), and in South America (n=26). No study has reported results yet.

Among the interventional studies, the most common primary purpose is the research on treatment (441; 75.3%), followed by prevention (79; 13.5%), supportive care studies (22; 3.8%), and diagnostic investigations (17; 2.9%). Regarding the drugs under scrutiny, hydroxychloroquine (110; 28.6%), azithromycin (38; 9.9%), lopinavir/ritonavir (24; 6.2%), interferon-α and -β (24; 6.2%), glucocorticoids (22; 5.7%), chloroquine (14; 3.6%), favipiravir (10; 2.6%), remdesivir (8; 2.1%), tocilizumab (21; 5.5%), anti-SARS-CoV-2 immunoglobulins (15; 3.9%) and sarilumab (9; 2.3%) account for the majority of interventional studies. Additional details are featured in [Table 2](#T2){ref-type="table"}.

###### Characteristics of COVID-19 interventional studies registered in ClinicalTrials.gov (n=586).

  -------------------------------------------
  Study type                     No. (%)
  ------------------------------ ------------
  Primary purpose (n=586)        

     Treatment                   441 (75.3)

     Prevention                  79 (13.5)

     Supportive care             22 (3.8)

     Diagnostic                  17 (2.9)

     Other                       13 (2.2)

     Screening                   5 (0.8)

     Basic science               5 (0.8)

     Health services research    4 (0.7)

  Drugs (n=385)                  

  *   Repurposed drugs*          

         Hydroxychloroquine      110 (28.6)

         Azithromycin            38 (9.9)

         Lopinavir/Ritonavir     24 (6.2)

         Glucocorticoids         22 (5.7)

         Interferon-α and -β     24 (6.2)

         Chloroquine             14 (3.6)

         Nitazoxanide            8 (2.1)

         Camostat                4 (1.0)

         Oseltamivir             4 (1.0)

         Ribavirin               1 (0.3)

      *Investigational agents*   

         Favipiravir             10 (2.6)

         Remdesivir              8 (2.1)

      *Adjunctive therapies*     

         Tocilizumab             21 (5.5)

         Anti SARS-CoV-2\        15 (3.9)
         immunoglobulins         

         Sarilumab               9 (2.3)
  -------------------------------------------

Discussion
==========

Our survey presents the current COVID-19 clinical research landscape. Several hundreds of clinical studies have been initiated all over the globe, and the number is growing. Most interventional studies incorporate randomisation, which is considered the hallmark of high-quality clinical trials ^[@ref-3]^, while more than 40% are blinded.

Studies are being conducted especially in the most affected areas: Europe and US. The number of COVID-19 cases in low to middle-income countries is still relatively low, also reflecting scarce testing, but is expected to rise in the next period. These countries will need more research on organizational measures, and trials on interventions that are affordable and applicable to those settings ^[@ref-4]^.

Most studies focus on adults and elderlies, while only few target children, possibly reflecting the observed burden of the disease. Additional effort is needed to ensure that minors are included in COVID-19 clinical research, so that therapeutic decisions are based upon high-quality evidence.

No drug with proven clinical efficacy currently exists for SARS-CoV-2 infection. Despite the absence of solid evidence, several treatments are being currently used in clinical practice in several countries, with sometimes disastrous consequences ^[@ref-5]^. Too many of the ongoing interventional studies have a small expected sample size, and may not generate credible evidence at completion ^[@ref-4]^. This might lead to a delayed recognition of effective therapies that are urgently needed, and a waste of time and resources. In the COVID-19 pandemic era, it is crucial that the adoption of new diagnostic, preventive and therapeutic strategies is based upon evidence coming from well-designed, adequately powered and carefully conducted clinical trials.

Data availability
=================

The Clinical Trials website can be accessed here: <https://clinicaltrials.gov/>
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